Pfizer to Launch New Treatment for Multiple Sclerosis

Case Type: new product, new technology; investment.
Consulting Firm: Trinity Partners first round full time job interview.
Industry Coverage: healthcare: pharmaceutical, biotech, life sciences.

Case Interview Question #01379: Multiple Sclerosis (MS) is a potentially disabling disease of the brain and spinal cord (central nervous system). In MS, the immune system attacks the protective sheath (myelin) that covers nerve fibers and causes communication problems between your brain and the rest of your body. Eventually, the disease can cause permanent damage or deterioration of the nerves. It can cause problems with vision, balance, muscle control, and other basic body functions.

Our client Pfizer Inc. is an American multinational pharmaceutical corporation headquartered in New York City, New York. The year is 2014. Recently the R&D department of Pfizer developed a new oral treatment for Multiple Sclerosis (MS), which has passed phase 2 of clinical trials. Before completing the rest of the clinical trial process, our client Pfizer wants a revenue projection for the drug in 2019, when the drug would hit peak sales. Specifically, the CEO Continue reading

Tagged , , , | Leave a comment

Amgen to Develop Treatment for Neonatal Congenital Disease

Case Type: new product, new technology; prioritization, optimization.
Consulting Firm: Trinity Partners first round full time job interview.
Industry Coverage: healthcare: pharmaceutical, biotech, life sciences.

Case Interview Question #01378: Our client, Amgen Inc. (NASDAQ: AMGN) is an American pharmaceutical company headquartered in Thousand Oaks, California. Focused on molecular biology and biochemistry, Amgen’s goal is to provide a healthcare solution based on recombinant DNA technology. In 2018, the company’s largest selling product lines were Neulasta, an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases.

The research and development (R&D) department of Amgen has invented new product called NeoFactor Drug (NFD), which could be used as a preventative treatment for two neonatal congenital diseases. In early studies, let’s assume this drug has the same efficacy and potential in both diseases. However, the client Amgen only has enough capital Continue reading

Tagged , , , | Leave a comment

Gilead Sciences to Commercialize Ear Infection Vaccines

Case Type: new product; investment.
Consulting Firm: ClearView Healthcare Partners first round full time job interview.
Industry Coverage: healthcare: pharmaceutical, biotech, life sciences.

Case Interview Question #01377: Our client Gilead Sciences, Inc. (NASDAQ: GILD) is a global biopharmaceutical company headquartered in Foster City, California, United States that researches, develops and commercializes drugs throughout the world. The company focuses primarily on antiviral drugs and vaccines used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi. Gilead is a member of the NASDAQ Biotechnology Index and the S&P 500.

Recently, Gilead Sciences is seeking new products to compliment its existing product lines. Gilead Sciences approached a small biotech firm, Ear-X LLC, to license its ear infection vaccine (EX1), which is currently at the final stage of clinical trials. Ear-X LLC is mainly a research and development (R&D) company and thus has no manufacturing or distribution capabilities. The current negotiated deal structure is USD $200M upfront and $15 per Continue reading

Tagged , , , | Leave a comment

Deepwater Horizon to Invest in Filtering Unit

Case Type: investment.
Consulting Firm: Analysis Group first round full time job interview.
Industry Coverage: oil, gas, petroleum industry.

Case Interview Question #01376: The client Deepwater Horizon Inc. is an oil refinery firm based in Texas, United States. An oil refinery is an industrial plant that refines crude oil into petroleum products such as diesel, gasoline, heating oils, kerosene, liquefied petroleum gas, jet fuel and fuel oils. Petrochemicals feed stock like ethylene and propylene can also be produced directly by cracking crude oil without the need of using refined products of crude oil such as naphtha.

The client Deepwater Horizon is looking at an investment in a filtering unit to transform residual oil into useful feedstock to produce gasoline (show Exhibit 1. Oil Refining Process). The inputs are crude oil which get refined to gasoline. Deepwater Horizon would like your help in determining whether they should invest in the filtering unit or not. What would you recommend?

Additional Information: (to provide upon request) Continue reading

Tagged , , | Leave a comment